08 NOV

Le Meridien Cambridge Boston

Le MERIDIEN

Proventa International's 6th Annual

ONCOLOGY

STRATEGY MEETING EAST COAST USA 2022

Exploring Promising Areas in Oncology Research Aimed to Expand Our Knowledge Base, Address Unmet Medical Needs and Improve Overall Clinical Success

- Cancer 'omics'
- Immuno-oncology
- Leveraging Biomarkers
- Radio-pharma-ceuticals
- Treating AML
- CAR-T
- Revamping ADCs
- NK cells
- CID Trials
- Precision Gene-Editing
- Vectors

Featuring Industry Leaders and Decision Makers

Laurent Audoly
Founder, CEO, Chairman of the Board
Parthenon Therapeutics

Geoffrey Hodge
Chief Executive Officer
SOTIO Biotech

Gregory Fiore
Chief Executive Officer
Exacis Biotherapeutics

George Tetz
Chief Executive Officer
CLS Therapeutics

Johanna Kaufmann
Executive Vice President Oncology
Codagenix Inc

Marco Gottardis
Vice President of Oncology Innovation
Janssen Pharmaceutical Companies of Johnson & Johnson

Vijay Kasturi
Vice President, Medical Affairs
AVEO Oncology

OUR SPONSORS

ARENSIA EXPLORATORY MEDICINE

Lunaphore

ProTrials

BasePair Biotechnologies, Inc.

sengenics

inato

Navinci

HAYSTACK ONCOLOGY

IDDI PASSION. SCIENCE. EXPERIENCE.

Click here to find out what our clients think about our **STRATEGY MEETINGS!**

Register Now! →

proventainternational.com

UK: +44 (0)20 3314 0100 | **US:** +1 (617) 614 0377

info@proventainternational.com

Proventa International

@proventaintl

@proventainternational

PROVENTA INTERNATIONAL

Proventa International's Strategy Meetings are a completely unique experience.

ONCOLOGY
STRATEGY MEETING
EAST COAST USA 2022

08 NOV

Our Vision

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format

ROUNDTABLE DISCUSSIONS

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.

INNOVATIVE SOLUTIONS

The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.

STRATEGIC NETWORKING

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

As one of the most significant areas of research in healthcare, the innovations stemming from cancer research are certainly commendable. Technologies such as the mRNA vaccine, brought to light by COVID were originally aimed at curing cancer, along with new approaches in discovering novel biomarkers, multi-omics approach to study cancer, epigenetic factors and reprogramming immune cells for enhanced efficacy, all of which are showing us a glimpse into the future. Constant advancements depict the need to keep pushing the limits of research to get to a stage where cancer is not a life-altering event, but at least a manageable, chronic condition. This strategy meeting intends to provide a stimulating environment where industry experts can discuss new discoveries, spark new collaborations and create synergy to accelerate progress in patients with cancer

Why this strategy meeting is a MUST ATTEND FOR YOU AND YOUR TEAM!

- How to Overcoming challenges for early phase I/O clinical trials and maximize opportunities for biomarker discovery
- What are the next generation ADC's?
- What is the need for a multi omics approach in cancer research?
- How can we leverage machine learning in clinical research to transform the future of evidence generation?
- Understanding how Non-Viral Vectors Compare with Viral Vectors for Application in Gene Therapy

SENIORITY OF ATTENDEES



- Director Level
- Department Head
- Other
- Team Lead
- Academia
- Scientist
- C-Level
- President / VP
- Manager

Facilitator Faculty

ONCOLOGY
STRATEGY MEETING
EAST COAST USA 2022

08 NOV

Dr. Claudia Hesselmann, PhD
Co-Founder & CEO, Germany
Arensia

Tatiana Eidus
Director Corporate Development North America, USA
Arensia

Déborah Heintze
Co-founder and Chief Marketing Officer
Lunaphore Technologies

Dr. Antonio Sorrentino
Head of Translational Strategy
Lunaphore Technologies

Andrew Jackson
U.S. Commercial Director
Sengenics

Katy McGirr
Director of Global Marketing
Sengenics

Laurent Audoly
Founder, CEO, Chairman of the Board
Parthenon Therapeutics

Vivian Choi
Head of Global Gene Therapy Research
Takeda

Tirtha Chakraborty
Chief Scientific Officer
Vor Biopharma

Sashka Dimitrievska
Global Therapeutic Area Head Oncology Clinical Insights
Astrazeneca

Gregory Fiore
Chief Executive Officer
Exacis Biotherapeutics

Marco Gottardis
Vice President of Oncology Innovation
Janssen Pharmaceutical Companies of Johnson & Johnson

Vijay Kasturi
Vice President, Medical Affairs
AVEO Oncology

Karuppiah Kannan
Executive Director - Global Program Leader
Takeda

Johanna Kaufmann
Executive Vice President Oncology
Codagenix Inc

Geoffrey Hodge
Chief Executive Officer
SOTIO Biotech

Jeffrey Humphrey
Member of Board of Directors
Cyteir Therapeutics

Chet Metcalf
Vice President, Head of Chemistry
Curie Therapeutics

Oscar Segurado
Chief Medical Officer
ASC Therapeutics

David Sherris
Biotechnology / Pharmaceutical Executive
Penrose Therapeutics

Reshma Singh
Director, Translational Medicine
Takeda

George Tetz
Chief Executive Officer
CLS Therapeutics

Intimate format events where senior leadership discuss the biggest challenges facing the industry.

Our Sponsors

Co-host Sponsors

ARENSIA EXPLORATORY MEDICINE is a German operator of proprietary research clinics in Eastern Europe, dedicated to performing complex Phase Ib, IIa and PROOF-OF-CONCEPT clinical trials with novel molecules, involving patients across numerous disease areas. Given the outstanding patient recruitment rates achieved by ARENSIA clinics, we are able to substantially reduce the overall number of sites, countries and recruitment periods for any early phase patient trial.

VISIT WEBSITE

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.

VISIT WEBSITE

ProTrials Research, Inc., is a full-service clinical research organization (CRO) and woman-owned business headquartered in Los Gatos, CA, with clinical operations personnel located throughout North America and across the world. ProTrials works with sponsors in the pharmaceutical, biotechnology and medical device industries to deliver high-quality clinical development services in a wide range of therapeutic areas. Founded in 1996, ProTrials has been successfully supporting clinical research for over 26 years.

VISIT WEBSITE

Base Pair Biotechnologies is based just 10 miles south of the Houston, Texas Medical Center. Our team of 11 scientists has a combined 50+ person-years of experience in developing aptamers. Base Pair owns the sole worldwide rights to patents for *multiplexed* aptamer discovery. We have the capability to select aptamers to up to 30 protein, peptide, or small molecule targets in true competitive, multiplexed fashion. The resulting aptamers are therefore more specific for their particular targets. Using this technology, we have completed contracts from the National Cancer Institute, the CDC, and many large pharma and biotech firms.

VISIT WEBSITE

Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics.

VISIT WEBSITE

Inato is a global marketplace that matches community-based research sites with the right clinical trials. The marketplace allows sponsors to confidently partner with a broader range of sites, making clinical trials more accessible, inclusive and effective. Since launching in June 2020, over 1400 sites have joined the marketplace along with several top-20 sponsors. Learn more at www.inato.com

VISIT WEBSITE

Navinci (formerly Olink AB) develops, produce and market high-performance reagent kits to serve scientists in academia, drug development and pathology research to accurately study proteins and their interplay directly in cells and tissue samples at a level not possible with other methods. Scientists use our in situ proximity ligation assay technology to better understand biological mechanisms and reveal the responses to disease and drug treatment. In particular, the effects of Immune Checkpoint Inhibitors can be studied in the tissue microenvironment giving higher chance of identifying strong drug candidates and to stratify patients that will benefit from treatment.

VISIT WEBSITE

Haystack Oncology uses the next generation of circulating tumor DNA (ctDNA) detection technology to see through the noise and uncover the lowest levels of ctDNA in blood to report residual, recurrent, or resistant disease earlier than any other minimal residual disease (MRD) test. Designed by cancer genomics pioneers and liquid biopsy experts, Haystack's tumor-informed MRD test is best positioned to deliver the right treatment to the right person at the right time.

VISIT WEBSITE

IDDI - eClinical and Biostatistical Services for phase I to IV trials since 1991
TRIAL DESIGN – RANDOMIZATION – DATA MANAGEMENT – BIOSTATISTICS

IDDI is an oncology expert company led by a highly-skilled biostatistical and clinical team of thought-leaders in oncology research. We combine biostatistics, regulatory & medical expertise with integrated eClinical solutions to ensure clinical data readiness for submission.

SERVICES:

- Trial design
- Statistical analyses
- IDMCs & Interim analyses
- IRT integrated with EDC system
- Data management
- Strategic consulting services
- Biomarker and diagnostics/IVD validation
- Support in Contacts with Regulatory Authorities
- Drug supply
- Medical coding
- CDISC Data Standardization

700+ oncology trials, 12 oncology FDA-EMA approvals

VISIT WEBSITE

How it Works?

ONCOLOGY
STRATEGY MEETING
EAST COAST USA 2022

08 NOV

Real insights are shared in conversations, not lectures. That's why our unique **roundtable** format guarantees real learning and ensures you only attend discussions that deliver value to you.

Join as many as four roundtable discussions, each with up to 20 other subject experts, networking with top-level peers in an informal, relaxed and sociable environment.

Simply follow the steps below to select your roundtable discussions and we'll create your own personalised agenda for the day:

01 EXPLORE THE FULL AGENDA

Select which roundtable discussions you would like to join. Our sessions are divided among 6 themed tracks for easy selection - you can choose to join any session you like.

02 COMPLETE YOUR SCHEDULING FORM

Select your preferred roundtable discussion for each time slot. We will send this form out via email a few weeks before the event - be sure to get your first choice by completing the form quickly.

03 ENJOY YOUR PERSONALISED EXPERIENCE

Join your selected roundtable sessions on the day. We will give you your personalised agenda containing the time and room assignments of your chosen roundtable discussions so you won't miss it.

Agenda at a Glance

Oncology Strategy Overview 8th of November, 2022 – Cambridge, Boston - Le Meridien Hotel

	TRACK 1	TRACK 2	TRACK 3	TRACK 4	TRACK 5	TRACK 6
TIME EST	BIOMARKER DISCOVERY	PRECISION MEDICINE/ COMPANION DIAGNOSTICS	ANTIBODY/ADC DISCOVERY & DEVELOPMENT	IMMUNO-ONCOLOGY	CLINICAL RESEARCH & DEVELOPMENT	CELL & GENE THERAPY
ROOM ►	Jerome C. Hunsaker C	Jerome C. Hunsaker	Jerome C. Hunsaker A	Lan Jen Chu	Margaret L.A. Macvicar	Edward Pennell Brooks
08:00 - 08:30	REGISTRATION AND WELCOME					
08:30 - 09:00	OPENING KEYNOTE PRESENTATION Drugging the Tumor Microenvironment to achieve durable response in patients					
09:00 - 10:00	Overcoming challenges for early phase I/O clinical trials and maximizing opportunities for biomarker discovery	Translating cancer 'omics' to improved outcomes	What is the next generation of ADC's?	Radioactivity - A particularly sensitive "antenna" with excellent tissue penetration	Role of machine learning in clinical research: transforming the future of evidence generation	Cell and Gene Therapy landscape in Hematological malignancies: Next-generation innovations beyond traditional Lentiviral CAR-T
10:00 - 10:10	REFRESHMENT BREAK					
10:10 - 10:30	NETWORKING / 1-1 MEETINGS					
10:30 - 10:50	NETWORKING / 1-1 MEETINGS					
10:50 - 11:10	NETWORKING / 1-1 MEETINGS					
11:10 - 12:10 SOLUTION	Auto antibody biomarkers for patient stratification: An approach to trial enrichment & drug repurposing SENGENICS	Funding early biotech companies in the Biden administration era with an emphasis on oncology		Tissue Biomarkers Innovations in Immuno-Oncology LUNAPHORE		
12:10 - 13:10	LUNCH BREAK					
13:10 - 13:40	ARENSIA EXPLORATORY MEDICINE	KEYNOTE PRESENTATION Accelerated performance of complex exploratory studies in oncology: Practical insights from investigational site			ARENSIA EXPLORATORY MEDICINE	
13:40 - 14:40	Innovative approaches towards implementing Predictive Biomarkers into Immuno-Oncology	Precision Gene-Editing Tools in Personalized Cancer Medicine and the challenges they pose		Leveraging the untapped potential of engineered T-cell based therapeutics to treat solid tumors	Incorporating real-time clinical insights in clinical development process for faster submissions and accelerated approvals	How do Non-Viral Vectors Compare with Viral Vectors for Application in Gene Therapy
14:40 - 14:50	REFRESHMENT BREAK					
14:50 - 15:10	NETWORKING / 1-1 MEETINGS					
15:10 - 15:30	NETWORKING / 1-1 MEETINGS					
15:30 - 15:50	NETWORKING / 1-1 MEETINGS					
15:50 - 16:50		The use of NK therapies for treatment of solid tumors – what are the problems and how do we move forward?		Challenges and Innovative Methods in Tumor-Targeted Approaches to Treat Solid Tumor Cancers	The use of Complex Innovative Design (CID) trials in Oncology	Next Generation Allogenic Cell Therapy
16:50 - 17:20	PANEL DISCUSSION Lost in translation: from preclinical to clinical – identifying problems and overcoming obstacles					
17:20 - 18:20	DRINKS & CANAPES RECEPTION					

Event Day

OPENING KEYNOTE PRESENTATION

8:30 – 9:00 EST

Drugging the Tumor Microenvironment to achieve durable response in patients

Laurent Audoly
Founder, CEO, Chairman of the Board
Parthenon Therapeutics

KEYNOTE PRESENTATION

13:10 – 14:40 EST

Accelerated performance of complex exploratory studies in oncology: Practical insights from investigational site

- Unique model of dedicated research clinics in Eastern Europe
- Strategies for fast patient enrollment and retention
- Operational tips for flawless study conduct
- Takeaways after operating under COVID-19 pandemic

Dr. Claudia Hesselmann, PhD
Co-founder & CEO, Germany
ARENSIA

Tatiana Eidus
Director Corporate Development
North America, USA, ARENSIA

ARENSIA

PANEL DISCUSSION

16:50 – 17:20 EST

Lost in translation: from preclinical to clinical – identifying problems and overcoming obstacles

[CHAIR] Reshma Singh
Director, Translational Medicine
Takeda

George Tetz
CEO
CLS Therapeutics

Johanna Kaufmann
Executive Vice President Oncology
Codagenix Inc

Jeffrey Humphrey
Member of Board of Directors
Cyteir Therapeutics

TRACK 1:
BIOMARKER DISCOVERY

Genetic, epigenetic, proteomic, glycolic, and imaging biomarkers can be used for cancer prognosis, diagnosis, and epidemiology. While some can be used to predict how aggressively your cancer will grow, and are therefore useful for assessing your prognosis, the most promising use of biomarkers today is to identify which therapies a patient's cancer may or may not respond to.

09:00 – 10:00 EST

ROUNDTABLE 1:
Overcoming challenges for early phase I/O clinical trials and maximizing opportunities for biomarker discovery

- What are appropriate patient populations for early phase clinical trials using I/O drugs both as monotherapy and in combination?
- How do we leverage novel trial designs for iterative testing of combinations and dose regimens and what are appropriate endpoints?
- How can we improve the identification of rational combination partners and optimally leverage biomarker programs?
- How much personalization is desirable or necessary in I/O drug development?

Johanna Kaufmann
Executive Vice President Oncology
Codagenix Inc

11:10 – 12:10 EST

SOLUTION FOCUS ROUNDTABLE 2:
Autoantibody biomarkers for patient stratification: An approach to trial enrichment & drug repurposing

- What clues is the immune system giving us about the patient population?
- How can biomarkers with high predictive value be found in heterogenous populations?
- How can novel technology overcome past limitations?

Andrew Jackson
U.S. Commercial Director
Sengenics

Katy McGirr
Director of Global Marketing
Sengenics

SENGENICS

13:40 – 14:40 EST

ROUNDTABLE 3:
Innovative approaches towards implementing Predictive Biomarkers into Immuno-Oncology

- Reviewing common issues encountered when translating a biomarker to the clinic: Determining eligibility for clinical study
- Practicalities that need to be considered when planning to use a biomarker to balance arms of a study
- Delineating a roadmap towards effective implementation of predictive patient-segmentation marker into an early clinical trial to facilitate subsequent development of effective CDx

Oscar Segurado
Chief Medical Officer
ASC Therapeutics

Event Day

TRACK 2:
PRECISION MEDICINE/COMPANION DIAGNOSTICS

Precision medicine has rapidly altered the oncology diagnostic and treatment spectrum by allowing tailored treatment strategies to precisely target the molecular alteration underlying individual patients' disease. With genomic-data sequencing new disease pathways are being discovered, new therapeutic targets are being revealed and ideal treatments populations are being identified which shall be discussed further in this track.

09:00 – 10:00 EST

ROUNDTABLE 1:
Translating cancer 'omics' to improved outcomes

- If a striking heterogeneity exists even at the very genomic level between histologically similar tumors, can that be leveraged in detecting important molecular alterations & identifying novel targets
- Understanding as target discovery further deepens, how important a multi omics approach which combines proteomics and genomic, is in cancer to considerably improve patient outcomes
- Focus on the unique advantages of a multidimensional approach and discuss the implications of the changing cancer demographic to translational omics research

Laurent Audoly
Founder, CEO, Chairman of the Board
Parthenon Therapeutics

11:10 – 12:10 EST

ROUNDTABLE 2:
Funding early biotech companies in the Biden administration era with an emphasis on oncology

- As the Biden administration leans into the Cancer Moonshot 2.0, would this program provide opportunity for the life sciences industry for precision oncology compared to Cancer Moonshot 1.0
- Will government controlled drug pricing be problematic for biotech/pharma R&D thereby negatively affecting the death rate from cancer
- What is the level of biotech funding for oncology compared to other diseases indications
- How does cancer therapeutic modalities affect decision to fund R&D

David Sherris
Biotechnology / Pharmaceutical Executive
Penrose Therapeutics

13:40 – 14:40 EST

ROUNDTABLE 3:
Precision Gene-Editing Tools in Personalized Cancer Medicine and the challenges they pose

- Gene-editing tools – CRISPR, Zinc Finger, TALENs and emerging tools hold promise to allow for engineering required to create potent, safe allogeneic cell therapies
- Discussing technical problems and that need to be addressed to incorporate innovative tools that drive next generation of molecular precision medicine
- Discuss strengths and limitations of each of the major approaches

Gregory Fiore
CEO
Exacis Biotherapeutics

15:50 – 16:50 EST

ROUNDTABLE 4:
The use of NK therapies for treatment of solid tumors – what are the problems and how do we move forward?

- There seems to be a barrier to NK therapies entering the solid tumor space
- Is the continued focus on hematologic malignancies due to limitations of NK cell therapies or due to lack of imagination?
- When hematologic malignancies make up 10% of cancer, Why is the field ignoring the other 90%?

Reshma Singh
Director, Translational Medicine
Takeda

Event Day

TRACK 3:
ANTIBODY/ANTIBODY DRUG CONJUGATE DISCOVERY & DEVELOPMENT

Traditional immunoglobulin antibodies have been further engineered for better efficacy and safety to specifically bind to a target antigen and release the cytotoxic drug into the cancer cell. This represents the newer generation of therapeutic antibody formats- bispecific antibodies and antibody–drug conjugates. This track explores the latest findings on antibody-based therapeutics and how to push the envelope in ADC manufacturing so they can be more effective.

09:00 – 10:00 EST

ROUNDTABLE 1:
What is the next generation of ADC's?

- New technologies expanding the scope of ADCs
  - — Novel Targets - is cellular internalization of the target necessary?
  - — Novel Toxins - what are the best or new targets?
  - — Novel Linkers - cleavable and non-cleavable
  - — Radioactive payloads
- Why understanding cell biology is critical to appropriately select the recommended phase II dose
- Novel approaches using "in vivo" chemistry to release linker-payload
  - — Future research using 2022's Nobel Prize winning "click chemistry" to release linker-payloads

Jeffrey Humphrey
Member of Board of Directors
Cyteir Therapeutics

TRACK 4:
IMMUNO-ONCOLOGY

Immuno-oncology is a form of cancer treatment that uses the power of the body's own immune system to prevent, control, and eliminate cancer. Of the many types of immunotherapy, checkpoint inhibitors form one arm of the treatment that works by blocking proteins that stop the immune system from attacking the cancer cells. This track will aim to uncover the mechanisms behind their resistance and explore the potential of an upcoming checkpoint inhibitor.

09:00 – 10:00 EST

ROUNDTABLE 1:
Radioactivity - A particularly sensitive "antenna" with excellent tissue penetration

- Can Radio pharmaceuticals deliver radiation to cancer cells, independent of their tumor type and location in the body?
- The advantages of nuclear imaging via SPECT and PET over other imaging modalities regarding sensitivity
- A major obstacle to development and effective application of novel therapeutic regimens is optimized patient selection and response assessment
  - — Noninvasive imaging using novel immunoconjugate radiopharmaceuticals can assess for expression of cell surface immune markers, such as programmed cell death protein ligand-1 (PD-L1), akin to a virtual biopsy
- Targeted radiopharmaceuticals provide very effective systemic treatment options due to the specific delivery of lethal radioactive doses to cancer tissues, while sparing healthy tissues
- How to leverage Radio-theranostics for diagnosis, staging, patients' stratification, and treatment, thus reinforcing precision medicine in oncology

Chet Metcalf
Vice President, Head of Chemistry
Curie Therapeutics

11:10 – 12:10 EST

SOLUTION FOCUS ROUNDTABLE 2:
Tissue Biomarkers Innovations in Immuno-Oncology

- Discussing the current landscape of immuno-oncology biomarkers: Tumor, Immune System and Microenvironment
- Immunotherapy Predictive Spatial Biomarkers: opportunities and challenges in the path to the clinic
- The Digital Pathology ecosystem and the role of pathologists, digital tools and techniques

Déborah Heintze
Co-founder and Chief Marketing Officer
Lunaphore Technologies

Dr. Antonio Sorrentino
Head of Translational Strategy
Lunaphore Technologies

LUNAPHORE

Lunaphore

13:40 – 14:40 EST

ROUNDTABLE 3:
Leveraging the untapped potential of engineered T-cell based therapeutics to treat solid tumors

- Improving manufacturing to produce more potent T cells
- Next generation CAR-Ts—novel transgenes to improve T cell performance
- Combination therapies with CAR-T

Geoffrey Hodge
CEO
SOTIO Biotech

Event Day

15:50 – 16:50 EST

ROUNDTABLE 4:
Challenges and Innovative Methods in Tumor-Targeted Approaches to Treat Solid Tumor Cancers

- How Immunotherapy falls ineffective when the tumor microenvironment (TME) is dominated by immunosuppressive cell types that impair immune response
- Discuss an approach that depletes such cells and increases the number of cancer-fighting immune cells
- Address key limitations to enable more effective treatment of solid tumor cancers

George Tetz
CEO
CLS Therapeutics

TRACK 5:
CLINICAL RESEARCH AND DEVELOPMENT

As tumor definitions become more granular, treatments become more specific, The velocity and variety of data is also accelerating in clinical trials, making integration and standardization more complex. Hence clinical and translational research also need to adapt to the rapidly changing environment to effectively translate novel concepts into sustainable and accessible therapeutic options for cancer patients.

09:00 – 10:00 EST

ROUNDTABLE 1:
Role of machine learning in clinical research: transforming the future of evidence generation

- ML has a role to play in maximizing the success and efficiency of trials during the planning phase through application of simulation techniques to large amounts of data
  — Study simulation may optimize the choice of treatment regimens for testing in non-small cell lung cancer
- An appealing application of ML is to automate data collection into case report forms, decreasing the time, expense, and potential for error associated with human data extraction
  — Though this use requires overcoming variable data structures and provenances, it has shown early promise in cancer

Karuppiah Kannan
Executive Director - Global Program Leader
Takeda

13:40 – 14:40 EST

ROUNDTABLE 3:
Incorporating real-time clinical insights in clinical development process for faster submissions and accelerated approvals

- Realizing the value of DS&AI driving oncology trial data for existing products label extension
- Can we apply clinical data insights from early to late stage trial designs to enable smarter trial designs
- Technology and analytics enabling biomarkers data to be gathered in real time – how do we apply this data to drive clinical trial endpoints

Sashka Dimitrievska
Global Therapeutic Area Head Oncology Clinical Insights
Astrazeneca

15:50 – 16:50 EST

ROUNDTABLE 4:
The use of Complex Innovative Design (CID) trials in Oncology

- The traditional cancer drug development pathway is increasingly being superseded by Complex Innovative Design (CID) trials that address multiple clinical questions
- Advantages of CID in assessing safety and toxicity of novel anticancer medicines and efficacy in biomarker-selected patients, specific cancer cohorts or in combination with other agents

Vijay Kasturi
Vice President, Medical Affairs
AVEO Oncology

Event Day

TRACK 6:
CELL & GENE THERAPY

Gene therapy involves the transfer of genetic material, usually via carrier or vector, and the uptake of that gene into the appropriate cells of the body while cell therapies involve the transfer of cells with the relevant function into the patient. Chimeric antigen receptor (CAR) T cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy and we investigate its potential in solid tumors in this track. Alongside we discuss a strategy that combines immune-modulation with better design of vectors.

09:00 – 10:00 EST

ROUNDTABLE 1:
Cell and Gene Therapy landscape in Hematological malignancies: Next-generation innovations beyond traditional Lentiviral CAR-T

- Cell Therapy Innovations for AML treatment: Regulatable and universal CARs, including T, NK and Macrophage
- Manufacturing challenges for viral and non-viral components
- Geno-Toxicity in cell and gene therapy and the expectation of the regulators

Tirtha Chakraborty
Chief Scientific Officer
Vor Biopharma

13:40 – 14:40 EST

ROUNDTABLE 3:
How do Non-Viral Vectors Compare with Viral Vectors for Application in Gene Therapy

- Limitations posed by current vectors such as immunogenicity, manufacturability, and payload
- AAV & beyond: progression in novel viral vectors
- Are there any particular disease areas/cell types that would benefit from a specific delivery modality?
- What are the current limitations of non-viral vectors, and how can they be overcome?

Vivian Choi
Head of Global Gene Therapy Research
Takeda

15:50 – 16:50 EST

ROUNDTABLE 4:
Next Generation Allogeneic Cell Therapy

- What are the new cell types being considered by allogeneic cell therapy? Advantages & Disadvantages
- What strategies are being used to achieve hypo - immunity?
- What hurdles are there to develop allogeneic cell therapies from IPSCs

Marco Gottardis
Vice President of Oncology Innovation
Janssen Pharmaceutical Companies of Johnson & Johnson

DRINKS & CANAPES RECEPTION

Please contact:
info@proventainternational.com
to register your interest

OR
SCAN HERE
TO REGISTER

Le MERIDIEN

ONCOLOGY
STRATEGY MEETING
EAST COAST USA 2022

08 NOV

Venue

Le Meridien Hotel - Cambridge, Boston

Le Méridien Cambridge-MIT's elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort.

BOOK ONLINE RESERVATION →
For more details email: In@proventainternational.com

MAP & DIRECTIONS →

OUR FACE-TO-FACE MEETING IN OCTOBER & NOVEMBER 2022

Strategy Meeting Zurich and Boston

Zurich - Europe

OCT 10 MON — CLINICALOPERATIONS
Clinical Operations Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 10 MON — CLINICALTRIALSUPPLYCHAIN
Clinical Trial Supply Chain Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 11 TUE — BIOMANUFACTURING
Biomanufacturing Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 11 TUE — CELLANDGENETHERAPY
Cell & Gene Therapy Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 12 WED — REGULATORYAFFAIRS
Regulatory Affairs Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 12 WED — CHEMISTRYMANUFACTURINGCONTROL
CMC Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 13 THUR — MEDICINALCHEMISTRY
Medicinal Chemistry Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

Boston/Cambridge MA - US East Coast

NOV 08 TUE — ONCOLOGY
Oncology Strategy Meeting 2022
Le Meridien Cambridge

NOV 09 WED — CLINICALOPERATIONS
Clinical Operations Strategy Meeting 2022
Le Meridien Cambridge

NOV 10 THUR — REGULATORYAFFAIRS
Regulatory Affairs Strategy Meeting 2022
Le Meridien Cambridge

NOV 14 MON — DRUG DISCOVERY BIOLOGY
Drug Discovery Biology Strategy Meeting 2022
Le Meridien Cambridge

NOV 15 TUE — MEDICINALCHEMISTRY
Medicinal Chemistry Strategy Meeting 2022
Le Meridien Cambridge

Exploring Promising Areas in ONCOLOGY RESEARCH Aimed to Expand Our Knowledge Base, Address Unmet Medical Needs and Improve Overall Clinical Success

Register Now! →
info@proventainternational.com